Eli Lilly’s Mounjaro tops Novo’s Wegovy in trial

Eli Lilly’s weight loss drug Mounjaro has demonstrated a 47% higher weight loss compared to Novo Nordisk’s Wegovy in a study, with patients losing an average of 22.8 kg over 72 weeks, versus 15 kg with Wegovy. Both drugs contain GLP-1 analogs, with Mounjaro including tirzepatid and Wegovy containing semaglutid, also found in Ozempic. The trial, named Surmount-5, tested on 751 American patients without diabetes. Although Mounjaro leads in weight loss, Wegovy has shown to reduce serious heart events and may be chosen by doctors for some overweight patients. Novo Nordisk also expects to release data on a potentially more effective weight loss drug, Cagrisema.